Eli Lilly's Revenue Soars 48%, Driven by Demand for Its GLP-1 Drugs

3-line summary

• Eli Lilly's revenue soared 48%, driven by demand for its GLP-1 drugs, according to the report.
• Sales were driven by higher-than-expected demand for Mounjaro and Zepbound, its GLP-1 drugs for Type 2 diabetes and weight loss, according to the report.

This summary is our own processing of the source article; see the source link below for full context.